396 related articles for article (PubMed ID: 31215680)
41. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.
Lord JD; Long SA; Shows DM; Thorpe J; Schwedhelm K; Chen J; Kita M; Buckner JH
Clin Immunol; 2018 Aug; 193():24-32. PubMed ID: 29842945
[TBL] [Abstract][Full Text] [Related]
42. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
43. Inflammatory bowel disease: exploring gut pathophysiology for novel therapeutic targets.
Yadav V; Varum F; Bravo R; Furrer E; Bojic D; Basit AW
Transl Res; 2016 Oct; 176():38-68. PubMed ID: 27220087
[TBL] [Abstract][Full Text] [Related]
44. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.
Abraham BP; Ahmed T; Ali T
Handb Exp Pharmacol; 2017; 239():115-146. PubMed ID: 28233184
[TBL] [Abstract][Full Text] [Related]
45. Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?
D'Amico F; Roda G; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):19-24. PubMed ID: 30848193
[TBL] [Abstract][Full Text] [Related]
46. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances.
Zundler S; Becker E; Schulze LL; Neurath MF
Gut; 2019 Sep; 68(9):1688-1700. PubMed ID: 31127023
[TBL] [Abstract][Full Text] [Related]
47. Effector T Helper Cell Subsets in Inflammatory Bowel Diseases.
Imam T; Park S; Kaplan MH; Olson MR
Front Immunol; 2018; 9():1212. PubMed ID: 29910812
[TBL] [Abstract][Full Text] [Related]
48. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.
Mosli MH; Rivera-Nieves J; Feagan BG
Drugs; 2014 Mar; 74(3):297-311. PubMed ID: 24452878
[TBL] [Abstract][Full Text] [Related]
49. Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis.
de Krijger M; Wildenberg ME; de Jonge WJ; Ponsioen CY
J Hepatol; 2019 Sep; 71(3):603-615. PubMed ID: 31108158
[TBL] [Abstract][Full Text] [Related]
50. Mucosal T cell proliferation and apoptosis in inflammatory bowel disease.
Sturm A; de Souza HS; Fiocchi C
Curr Drug Targets; 2008 May; 9(5):381-7. PubMed ID: 18473766
[TBL] [Abstract][Full Text] [Related]
51. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease.
Belarif L; Danger R; Kermarrec L; Nerrière-Daguin V; Pengam S; Durand T; Mary C; Kerdreux E; Gauttier V; Kucik A; Thepenier V; Martin JC; Chang C; Rahman A; Guen NS; Braudeau C; Abidi A; David G; Malard F; Takoudju C; Martinet B; Gérard N; Neveu I; Neunlist M; Coron E; MacDonald TT; Desreumaux P; Mai HL; Le Bas-Bernardet S; Mosnier JF; Merad M; Josien R; Brouard S; Soulillou JP; Blancho G; Bourreille A; Naveilhan P; Vanhove B; Poirier N
J Clin Invest; 2019 Apr; 129(5):1910-1925. PubMed ID: 30939120
[TBL] [Abstract][Full Text] [Related]
52. The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.
Zundler S; Fischer A; Schillinger D; Binder MT; Atreya R; Rath T; Lopez-Pósadas R; Voskens CJ; Watson A; Atreya I; Neufert C; Neurath MF
Inflamm Bowel Dis; 2017 Mar; 23(3):379-391. PubMed ID: 28221249
[TBL] [Abstract][Full Text] [Related]
53. [Targeting and role of α4β7 integrin in the pathophysiology of IBD and HIV infection].
Girard A; Rochereau N; Roblin X; Genin C; Paul S
Med Sci (Paris); 2015 Oct; 31(10):895-903. PubMed ID: 26481029
[TBL] [Abstract][Full Text] [Related]
54. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies.
Tian T; Wang Z; Zhang J
Oxid Med Cell Longev; 2017; 2017():4535194. PubMed ID: 28744337
[TBL] [Abstract][Full Text] [Related]
55. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
Bravatà I; Fiorino G; Allocca M; Repici A; Danese S
Scand J Gastroenterol; 2015 Jan; 50(1):113-20. PubMed ID: 25523561
[TBL] [Abstract][Full Text] [Related]
56. Inhibiting PGGT1B Disrupts Function of RHOA, Resulting in T-cell Expression of Integrin α4β7 and Development of Colitis in Mice.
López-Posadas R; Fastancz P; Martínez-Sánchez LDC; Panteleev-Ivlev J; Thonn V; Kisseleva T; Becker LS; Schulz-Kuhnt A; Zundler S; Wirtz S; Atreya R; Carlé B; Friedrich O; Schürmann S; Waldner MJ; Neufert C; Brakebusch CH; Bergö MO; Neurath MF; Atreya I
Gastroenterology; 2019 Nov; 157(5):1293-1309. PubMed ID: 31302143
[TBL] [Abstract][Full Text] [Related]
57. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
Rivera-Nieves J
Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
[TBL] [Abstract][Full Text] [Related]
58. A Decade of Th9 Cells: Role of Th9 Cells in Inflammatory Bowel Disease.
Vyas SP; Goswami R
Front Immunol; 2018; 9():1139. PubMed ID: 29881387
[TBL] [Abstract][Full Text] [Related]
59. IBD immunopathogenesis: A comprehensive review of inflammatory molecules.
Park JH; Peyrin-Biroulet L; Eisenhut M; Shin JI
Autoimmun Rev; 2017 Apr; 16(4):416-426. PubMed ID: 28212924
[TBL] [Abstract][Full Text] [Related]
60. Role of MiRNAs in Inflammatory Bowel Disease.
Cao B; Zhou X; Ma J; Zhou W; Yang W; Fan D; Hong L
Dig Dis Sci; 2017 Jun; 62(6):1426-1438. PubMed ID: 28391412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
